Capital Cell

MgShell develops intraocular devices for treating age-related macular degeneration and other retinal diseases. Their innovative technology mimics current clinical practices with a single injection, autonomously releasing therapeutic drugs at predetermined intervals without requiring additional surgical procedures.

MSInsight is a bioinformatics startup specializing in the development of diagnostic and treatment response prediction solutions for microsatellite instability (MSI) cancers. The company offers a platform that utilizes next-generation sequencing data to analyze MSI status, a crucial biomarker in oncology. By providing actionable insights on this biomarker, MSInsight enables healthcare professionals to make informed decisions about patient care, particularly concerning treatment options such as immunotherapy. The focus on diagnostic and prognostic biomarkers of treatment response enhances the ability to improve overall patient outcomes in the oncology market.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

Affirma Biotech is a biotechnology research company focused on the development of host-directed drugs aimed at treating chronic and severe infectious diseases. The company employs innovative host-directed therapy strategies to target host cell factors that pathogens need for replication and persistence. Specializing in immunomodulation, Affirma Biotech engages in the discovery and development of new anti-infective drugs, contributing to the creation of orally available immunotherapeutic options for severe infections and cancer. By managing the development of pharmaceutical products throughout the value chain, the company seeks to provide effective therapeutic tools that address urgent global health challenges posed by viral infections.

MediQuo is a health tech company that provides a chat-based medical consultation app connecting patients and healthcare professionals for remote health interactions. The platform supports secure messaging, video and audio calls, and the exchange of files such as medical reports and lab results to aid diagnosis and appointment management. It emphasizes privacy and regulatory compliance, maintains patient medical history, and offers 24/7 medical responses through a professional network for health information and professional discovery. The service enables discussions, appointments, and rapid consultations with doctors and specialists, and has facilitated over 1 million consultations and more than 600,000 downloads, ranking among the leading health apps in Spain and Latin America.

Loop Dx is developing point-of-care diagnostics for faster detection of sepsis to reduce sepsis mortality, patient side effects, and antibiotic resistance due to unnecessary provided antibiotics. We want to facilitate healthcare providers the tools they need for faster sepsis identification saving lives and optimizing sepsis management.

Exheus tells everything that you need to know to take maximum care of yourself and avoid risks to your health, exheus is much more than a DNA test that only indicates which genes you have.

Founded in 2013 by researchers specializing in drug development, Oncostellae focuses on discovering and developing small molecule drugs for cancer treatment. The company manages its R&D process with a lean team, concentrating on project management, medicinal chemistry, and in vitro pharmacology while outsourcing other activities to qualified providers. Its strategic goal is to license a clinical drug candidate to a pharmaceutical or biotechnology company.

Inrobics is a company focused on enhancing rehabilitation through the integration of artificial intelligence and social robots. It offers a cloud-based platform that supports individuals with functional and neurological limitations, facilitating personalized treatment both in rehabilitation centers and at home. By developing robotics that promote interaction between patients and healthcare professionals, Inrobics aims to improve the quality of rehabilitation treatments. Their technology addresses various challenges faced by clients, including those stemming from brain damage and neurodevelopmental disorders, thereby providing essential support, well-being, and educational resources to enhance the rehabilitation experience.

Mowoot is a company that specializes in developing wearable medical devices aimed at improving the quality of life for individuals suffering from chronic constipation. Founded in 2014 and based in Barcelona, Spain, Mowoot offers a non-pharmacological and non-invasive solution that simulates a manual abdominal massage performed by healthcare professionals. Utilizing advanced pneumatic technology, its device provides automatic colon-specific massages to stimulate intestinal transit, thereby helping to treat and prevent chronic slow transit constipation without the need for colon cleansing supplements, enemas, or laxatives. Mowoot emerged from the MOEBIO dHEALTH program, drawing inspiration from concepts in design and business innovation.

Kintsugi Therapeutics is a preclinical biopharmaceutical company focused on developing therapies targeting endoplasmic reticulum stress regulation. Their primary focus is treating liver conditions, including non-alcoholic steatohepatitis (NASH), aiming to improve patients' lives.

FrontWave Imaging is a developer of advanced medical imaging technology specializing in 3D ultrasound for breast cancer diagnosis. The company creates software that leverages supercomputing to enhance the quality of ultrasound images, thereby improving diagnostic accuracy. Its system facilitates a comprehensive workflow, including data transfer to the cloud, image reconstruction, and visualization through an intuitive user interface. This innovative approach allows healthcare professionals to monitor breast tumors effectively while minimizing patient exposure to harmful ionizing radiation. FrontWave Imaging aims to transform the medical diagnosis landscape for breast cancer by providing enhanced imaging capabilities and supporting better patient outcomes.

Corify Care is a Madrid-based developer of non-invasive medical technology for cardiac arrhythmias, focusing on atrial fibrillation. The company creates a device that can visualize the heart's electrical activity without catheters or invasive imaging, enabling real-time electrocardiographic imaging and electro-anatomical mapping during routine cardiology visits. Its ACORYS system addresses limitations of existing methods by providing activation patterns at multiple points of the heart to help clinicians identify a patient-specific origin of atrial fibrillation and guide treatment decisions non-invasively. Founded in 2019, Corify Care aims to improve clinical management of arrhythmias through accessible, non-surgical mapping that supports safer, faster diagnosis and planning.

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

Ekuore is a technology company based in Valencia, Spain, founded in 2012, that specializes in the design, development, and marketing of medical devices that integrate health services with mobile technologies. The company focuses on creating mHealth devices aimed at revolutionizing sanitary teleassistance, allowing for efficient and cost-effective monitoring and control of patients. Ekuore's flagship product is a digital electronic stethoscope designed to track and monitor patients' conditions, particularly in diagnosing cardiovascular diseases. This device compares physiological parameters against a comprehensive database to provide objective diagnoses, enabling hospitals to conduct secure digital consultations and enhance patient care.

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

QMENTA is a software company specializing in medical imaging management. They offer cloud-based solutions for clinical trials, neuroimaging disease packages, and neuro-data services, enabling efficient collection, processing, and analysis of large-scale brain images.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Laminar Pharma is an innovative biopharmaceutical company dedicated to the discovery, rational design, and early clinical development of a new generation of medicines through a unique therapeutic approach known as Membrane Lipid Therapy (MLT). The company specializes in developing MLT-based drugs, as well as nutraceuticals and cosmetic products, all aimed at enhancing treatment options for physicians by targeting membrane lipids. By leveraging this novel strategy, Laminar Pharma seeks to advance healthcare solutions and improve patient outcomes with its cutting-edge therapeutic offerings.

Tractivus is a biotechnology company specializing in innovative medical device solutions. They develop implantable devices with nanocoatings that resist bacterial colonization, extending product lifespan and reducing healthcare costs.

Rithmi develops innovative, non-invasive technology for real-time arrhythmia detection. Its pioneering product aims to revolutionize stroke prevention by providing accurate heart pulse data through light reflection on the skin, closely matching ECG accuracy.

RheoDx is a developer of a diagnostic medical device focused on enhancing the quality of life for hematology patients. The company's innovative technology measures the behavior of blood in motion, utilizing a sample as small as a drop to detect subtle changes in the rheological properties of red blood cells. These changes can indicate abnormalities in cell morphology or rigidity, which are linked to various diseases, including blood coagulation disorders, malignant homeopathies, malaria, and hereditary anemias. The device's compact size and user-friendly design enable point-of-care testing and home use, empowering patients to monitor their conditions conveniently and affordably.

Derma Innovate is a biotechnology company focused on skin and hair regeneration. It develops topical compounds designed to be stimulated by light to trigger local biological processes that promote tissue regeneration, with the aim of delivering advanced skin and hair regeneration products.

Fesia Technology S.L., established in 2016 and headquartered in Donostia, Spain, specializes in developing medical devices for neurorehabilitation. The company focuses on individuals who have experienced injuries or neuromuscular diseases such as stroke, spinal cord injury, cerebral palsy, and multiple sclerosis. Fesia's primary product, Fesia Walk, is a rehabilitation device designed for foot drop patients, utilizing a novel system of functional stimulation via a matrix-arranged electrode. This technology aims to enhance rehabilitation therapy and improve the lives of those affected by these conditions.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Arcis Biotechnology Limited specializes in the development and commercialization of nucleic acid sample preparation solutions. The company offers a range of ready-to-use kits, including the Arcis Sample Prep Kit, which facilitates the extraction of nucleic acids from diverse sample types such as whole blood, saliva, and various biological materials. Arcis’s DNA products enable rapid processing, allowing users to obtain genetic material in under three minutes without the need for laboratory equipment, using minimal sample volumes. Their technology supports applications in point-of-care diagnostics, veterinary research, and forensic analysis. Additionally, Arcis provides technical support services and distributes its products across several countries, including the United Kingdom, Ireland, and India. Founded in 2013 and based in Warrington, United Kingdom, the company was previously known as Arcis Molecular Limited before rebranding in 2018.

Founded in Barcelona, Spain in 2014, Adan Medical Innovation develops innovative medical devices focused on improving the management of anaphylaxis. Their flagship product, AnAPPhylaxis, is a smart case for epinephrine auto-injectors connected to a mobile app, providing users with real-time condition monitoring and reminders, while also offering clear action plans in emergency situations.

Cebiotex specializes in drug delivery technology using electrospun nanofibers. It offers contract research services and has developed biocompatible, biodegradable membranes for controlled release of active agents, primarily focused on treating unresectable tumors.

Davalor Salud is a company focused on enhancing functional visual health through innovative technology. It develops and commercializes both hardware and software designed for the exploration and diagnosis of visual function. The company offers accessible services that autonomously measure vision and provide visual training using advanced 3D video game technology. By specializing in the diagnosis and therapy of functional visual health issues, Davalor Salud aims to improve the quality of life for its users, making effective visual health services more widely available to the public.

MJN improves the quality of life of people suffering from epilepsy thanks to our wearable ear piece that performs an EEG of the patient. By applying AI algorithms, MJN-SERAS is able to interpret the brain signal, record epileptic seizures, objectively improve the medical monitoring and permanently assess the risk of suffering an epilepsy seizure

Biohope is focused on creating diagnostic and therapeutic solutions specifically for organ transplantation. The company has developed a system aimed at providing immunological clinical management for kidney transplant patients. By analyzing a patient's blood sample, Biohope's system allows for the customization of treatment with immunosuppressive drugs. This tailored approach not only aids in the prevention of organ rejection but also extends its utility to the treatment of autoimmune diseases such as arthritis. Through its innovative technology, Biohope seeks to enhance patient outcomes in the field of transplantation and immunology.

Vytrus Biotech SL is a biotechnology company based in Barcelona, Spain, that specializes in the development, production, and commercialization of active ingredients derived from plant stem cells. Founded in 2009 as a spin-off from the University of Barcelona, the company leverages over 30 years of research in plant biotechnology to create high-value natural active ingredients primarily for the cosmetics and pharmaceutical industries. Its product offerings include a range of cosmetic solutions such as cell factor-rich plasma and phyto-peptidic fractions, as well as dermatologic and customized products. In 2016, the company changed its name from Phyture Biotech SL to Vytrus Biotech SL, reflecting its focus on innovative, plant-based active ingredients.

Absynth Biologics Limited is a biotechnology company focused on discovering and developing vaccines and therapeutic antibodies aimed at preventing and treating bacterial infections. Founded in 2007 and based in Alderley Edge, United Kingdom, the company targets significant pathogens, including Staphylococcus aureus, Clostridium difficile, and Streptococcus pyogenes. Utilizing a platform that identifies novel protein antigen targets, Absynth Biologics employs a dual-action mechanism that combines direct antibacterial activity through antibody-mediated effects and the engagement of immune effector functions to eliminate bacteria. By characterizing specific proteins from these bacteria as immunological targets, the company aims to enhance patient immunity and address serious health threats associated with bacterial infections.

Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing innovative therapies for inflammation and autoimmune diseases. Established in 2014, the company specializes in modifying a naturally occurring protein that plays a crucial role in immunoregulation. Ducentis targets the CD200/CD200R axis, which provides a deactivating signal to activated immune cells in both the innate and adaptive immune systems. The company's research aims to address various therapeutic needs, including transplant rejection and a range of autoimmune and inflammatory conditions affecting organs such as the lungs, liver, kidneys, eyes, bones, and cartilage.

TBIOM biotechnological startup that aims to develop sustainable medical products and solutions to help large sectors of the population. TBIOM is working on the development of different electronic mhealth devices such as the control system for chronic alcoholism ETHAXIP (intra-oral device) or the DALVC system for performing continuous bladder washes in hospital centers. This last device is being developed jointly with Vecmedical and Vall d'Hebrón Hospital . In addition, TBIOM has developed and patented a new CPAP device for sleep apnea, portable, autonomous and mHealth , which also manages and encourages the health and care of people with this respiratory difficulty called Airmony.

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Cebiotex specializes in drug delivery technology using electrospun nanofibers. It offers contract research services and has developed biocompatible, biodegradable membranes for controlled release of active agents, primarily focused on treating unresectable tumors.

The Pump it Nanotech S.L is a Start Up born from the Pump it project. This project was a response to the challenge presented by SENER, regarding the troublesome behaviour of bubbles in microfluidic devices in microgravity, during the 5th Ideas Generation Program: Aeroespacial Technologies from UAB (PRUAB).

Bioprognos is a Barcelona-based company spun off from Hospital Clínic. It focuses on developing innovative, non-invasive diagnostic solutions to enhance clinical outcomes and improve quality of life for cancer patients.

Cebiotex specializes in drug delivery technology using electrospun nanofibers. It offers contract research services and has developed biocompatible, biodegradable membranes for controlled release of active agents, primarily focused on treating unresectable tumors.

Braingaze develops eye‑tracking technology that captures a unique small involuntary eye movement biomarker. The system uses functional games to elicit the movement, then applies deep‑learning algorithms trained on real patient and control data to assess cognitive function. It targets pre‑symptomatic Alzheimer’s disease and ADHD, offering diagnostic tools and digital therapies that have demonstrated symptom reduction of over 50%. The products are CE‑marked medical devices and are available on the market.

Capital Cell is a European equity crowdfunding platform based in Barcelona, Spain, that specializes in biotechnology and life sciences projects. Founded in 2014, the company serves as a meeting point for entrepreneurs and private investors, including venture capitalists and business angels, to facilitate funding for innovative medical science initiatives. By leveraging the power of the crowd, Capital Cell enables researchers and companies in the biotech sector to access a diverse pool of investment, thereby fostering the growth and development of cutting-edge solutions in healthcare.

QMENTA is a software company specializing in medical imaging management. They offer cloud-based solutions for clinical trials, neuroimaging disease packages, and neuro-data services, enabling efficient collection, processing, and analysis of large-scale brain images.

ZeClinics is a biotechnology start-up that specializes in drug and pharmaceutical development using zebrafish as a model organism. The company provides an outsourcing solution for safety and efficacy screenings of novel chemical compounds. Utilizing its advanced platform, ZeClinics conducts toxicology screenings by tracking toxicity data and preserving embryos of marine species. The company employs zebrafish larvae to evaluate the toxicity of drugs and related protein molecules, allowing biotechnologists to assess drug safety and recommend appropriate dosages. Through its innovative approach, ZeClinics aims to enhance the drug development process by offering reliable and efficient testing solutions.

Developing a genetic test to help reduce the risk of hospital infections.